InvestorsHub Logo
Post# of 251715
Next 10
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 188542

Wednesday, 05/06/2015 11:21:21 AM

Wednesday, May 06, 2015 11:21:21 AM

Post# of 251715
BMY’s HCV approach in all markets except Japan is to focus on GT3 and niche market segments. (Source: today’s DB webcast.)

This confirms that (contrary to what was written in BioCentury), BMY does not intend to submit an NDA or MAA for its 3-DAA regimen for GT1 patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.